Data and analytics company, GlobalData, has revealed that recent survey findings from the European Medicines Agency (EMA) into Brexit preparedness of the pharma industry support its own conclusions on the matter.
Brexit rethink
The EMA survey, published earlier this week, identified gaps in the preparedness of the pharma industry in relation to Brexit, indicating a potential risk to supply of medicines after the UK’s withdrawal from the European Union next year (2019).